-
Jul 3, 2024 Apotex Further Expands Oncology Franchise Through the Acquisition of Canadian Rights to Toripalimab
-
Jun 3, 2024 Apotex Completes Acquisition of Searchlight, a leading Canadian-based Specialty Innovative Branded Pharmaceutical Company
-
Apr 2, 2024 Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader
-
Feb 16, 2024 Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
-
Aug 9, 2023 Voluntary Recall of seven ( 7 ) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard)
-
Aug 9, 2023 Voluntary Recall of three ( 3 ) lots of APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP)
-
Apr 3, 2023 SK Capital completes acquisition of Apotex, a global leader in affordable pharmaceuticals
-
Feb 1, 2023 Voluntary Recall of one ( 1 ) lot of APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg - Lot PY1904
-
Dec 16, 2022 Accessa becomes the patient support program manager for Apotex Inc.'s Apo-Deferasirox™ and Apo-Deferasirox (Type J)™ products.
-
Sep 28, 2022 SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals
-
Jul 27, 2022 Voluntary Recall of four ( 4 ) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) 200 mg and 800 mg
-
Jul 20, 2022 First Generic Alternative to Eliquis® Now Available in Canada
-
May 17, 2022 Apotex Launches Affordable Generic Option to Treat Relapsing Remitting Multiple Sclerosis
-
Apr 26, 2022 Voluntary Recall of five ( 5 ) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) 200 mg and 800 mg.
-
Jan 19, 2022 Voluntary Recall of one ( 1 ) lot of APO- AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg – Lot PY1832.
-
Nov 30, 2021 Canada-Wide Contest Recognizes the Impact of Pharmacy Professionals on Patient Care
-
Nov 9, 2021 Patient Access to Affordable Cancer Treatment Increases with the Launch of New Biosimilar in Canada
-
Sep 30, 2021 VOLUNTARY NATIONWIDE RECALL: ONE LOT OF Mirvala™ 28 (Desogestrel and Ethinyl Estradiol Tablets, USP) 0.150 mg / 0.030 mg DUE TO POSSIBILITY OF ONE PLACEBO PILL IN PLACE OF AN ACTIVE PILL
-
Sep 27, 2021 Canadian Cancer Patients Have New Affordable Treatment Option
-
Sep 1, 2021 CANADIAN-MADE GENERIC OPTION TO TREAT MULTIPLE MYELOMA NOW AVAILABLE
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 9, 2026
Apotex to announce second quarter fiscal 2027 financial results and host conference call on Nov. 12, 2026
TORONTO, Oct. 8, 2026 /CNW/ -- Apotex Health Corp.("Apotex") (TSX: APTX) today announced that it will issue a press release with its second quarter Fiscal 2027 financial results on Thursday, November 12, 2026, at approximately 6:00 a.m. ET. Apotex will host a conference call and live webcast to discuss the results at 8:00a.m. ET.
-
Oct 5, 2026
Apotex Health Corp. announces closing of $1,250 million inaugural senior unsecured notes offering
Toronto, Ontario, October 5, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today the closing of the previously announced offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Offering was made through a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.
-
Sep 29, 2026
Apotex Health Corp. announces $1,250 million inaugural senior unsecured notes offering
Toronto, Ontario, September 28, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today that it has priced a private placement offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Notes are being offered on an agency basis by a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.